Combination oral contraceptive pills offer BMI, lipid benefit in PCOS

  • Li L & al.
  • BMC Womens Health
  • 27 Feb 2020

  • curated by Elisabeth Aron, MD, MPH, FACOG
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The combination of 3 mg drospirenone (DRSP) and 20 μg ethinyl estradiol (EE) has favorable metabolic and hormonal effects in people with PCOS.

Why this matters

  • DRSP has antimineralocorticoid and antiandrogenic activities.
  • The prevalence of PCOS among reproductive-age women is 6%-10%.

Key results

  • Improvements in metabolic and hormonal profile after 3 months of DRSP/EE tablets:
    • Decreased BMI (P<.001 waist-hip ratio>
    • Decreased testosterone (P<.001>
    • Increased high-density lipoprotein-cholesterol (P<.001>
    • Decreased ovarian volume (P<.05>
  • No change in blood glucose levels or insulin resistance.
  • 42.14% of patients reported discomfort including gastrointestinal disorder, dizziness, headache, breast swelling, or irregular bleeding.

Study design

  • Single-center, prospective, observational study.
  • Patients with PCOS were prescribed once daily DRSP/EE tablets (n=140).
  • Anthropometric measurements, sex hormones, glucolipid metabolic index, ovarian volume, and adverse effects were recorded at baseline and after 3 months of treatment.
  • Funding: Science and Technology Planning Project of Guangdong Province; Key Project of Guangdong Provincial Administration of Traditional Chinese Medicine; Guangzhou Municipal Science and Technology Innovation Council.

Limitations

  • Small sample size.
  • Retrospective study.
  • Single center, so results may not be generalizable.